References
- Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer. Nature Rev Cancer 2005; 5: 459–67
- Rehfeld JF, van Solinge WW. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res 1994; 63: 295–346
- Rehfeld, JF. Gastrin and cancer. In:. A Kastin, editor. Handbook of biologically active peptides. San DiegoCalif., USA: Elsevier Science; 2006. In press.
- Seva C, Dickinson CJ, Yamada T. Growth-promoting effects of glycine-extended progastrin. Science 1994; 265: 410–12
- Bardram L, Rehfeld JF. Production and evaluation of monospecific antibodies for a processing-independent sequence of human progastrin. Scand J Clin Lab Invest 1989; 49: 173–82
- Makishimi R, Larkin P, Michaeli D, Gaginella TS. Active immunization against gastrin-17 with an N-terminal derived immunogen inhibits gastric and duodenal lesions in rats. Gastroenterology 1994; 106: A824
- Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A, et al. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 1996; 56: 880–5
- Smith AM, Justin T, Michaeli D, Watson SA. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res 2000; 6: 4719–24
- Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, et al. Phase II study of antigastrin-17-antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002; 20: 4225–31
- Aphton Corporation. Gastrin 17 vaccine – Aphton: Anti-gastrin 17 immunogen G17DT. Biodrugs 2003;17:223–5.
- Goetze JP, Nielsen FC, Burcharth F, Rehfeld JF. Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 2000; 88: 2487–94